{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:13:46Z","timestamp":1784157226214,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jaad.2018.03.036","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T18:45:26Z","timestamp":1522435526000},"page":"353-359.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Biologics for pityriasis rubra pilaris treatment: A review of the literature"],"prefix":"10.1016","volume":"79","author":[{"given":"Monica","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Abeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.03.036_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","article-title":"Pityriasis rubra pilaris","volume":"5","author":"Griffiths","year":"1980","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(89)70093-1","article-title":"Pityriasis rubra pilaris: a review of diagnosis and treatment","volume":"20","author":"Cohen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11530070-000000000-00000","article-title":"Pityriasis rubra pilaris: a review of diagnosis and treatment","volume":"11","author":"Klein","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-017-0338-1","article-title":"A review on pityriasis rubra pilaris","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jaci.2017.05.019","article-title":"Autoinflammatory keratinization diseases","volume":"140","author":"Akiyama","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2018.03.036_bib6","article-title":"Pityriasis rubra pilaris: algorithms for diagnosis and treatment","author":"Roenneberg","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients","volume":"152","author":"Ross","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaad.2018.03.036_bib9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjd.12952","article-title":"Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a\u00a0novel mutation in CARD14","volume":"171","author":"Eytan","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib10","article-title":"Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14","author":"Lwin","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000337546","article-title":"Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?","volume":"224","author":"Ivanova","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.03.036_bib12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd4518","article-title":"Targeting the IL-17-T(H)17 pathway","volume":"14","author":"Bartlett","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2018.03.036_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2147\/CCID.S124351","article-title":"Management of refractory pityriasis rubra pilaris: challenges and solutions","volume":"10","author":"Moretta","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/120347540500900605","article-title":"Off-label dermatologic uses of anti-TNF-a therapies","volume":"9","author":"Alexis","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2018.03.036_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jaad.2018.03.036_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14712598.8.1.123","article-title":"Infliximab in dermatological treatment: beyond psoriasis","volume":"8","author":"Rigopoulos","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2018.03.036_bib19","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1111\/j.1468-3083.2012.04456.x","article-title":"A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists","volume":"27","author":"Petrof","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12559","article-title":"Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: a retrospective investigation","author":"Maloney","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.03.036_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1346-8138.14114","article-title":"Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases","volume":"45","author":"Napolitano","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamadermatol.2016.3885","article-title":"Successful treatment of refractory pityriasis rubra pilaris with secukinumab","volume":"152","author":"Schuster","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jdcr.2016.09.006","article-title":"Successful treatment of type II pityriasis rubra pilaris with secukinumab","volume":"2","author":"Gauci","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2018.03.036_bib24","article-title":"Resolving classic pityriasis rubra pilaris, mimicker of erythema gyratum repens","author":"Davenport","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib25","first-page":"844","article-title":"Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept","volume":"9","author":"Vasher","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/120347540300700503","article-title":"Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses","volume":"7","author":"Drosou","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2018.03.036_bib27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/archderm.141.4.423","article-title":"Infliximab for the treatment of adult-onset pityriasis rubra pilaris","volume":"141","author":"Liao","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib28","first-page":"18","article-title":"Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab","volume":"12","author":"Lu","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2018.03.036_bib29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1440-0960.2006.00247.x","article-title":"Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab","volume":"47","author":"Manoharan","year":"2006","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2340\/00015555-0308","article-title":"Pityriasis rubra pilaris successfully treated with infliximab","volume":"87","author":"Ruiz-Genao","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1468-3083.2007.02282.x","article-title":"Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab","volume":"22","author":"Ruzzetti","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib32","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2008.05.037","article-title":"Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy","volume":"59","author":"M\u00fcller","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib33","first-page":"1071","article-title":"Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate","volume":"7","author":"Barth","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2018.03.036_bib34","first-page":"439","article-title":"Pityriasis rubra pilaris\u2013a retrospective single center analysis over eight years","volume":"8","author":"Gemmeke","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2018.03.036_bib35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1468-3083.2009.03511.x","article-title":"Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series","volume":"24","author":"Garcovich","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1684\/ejd.2011.1325","article-title":"Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris","volume":"21","author":"Dessinioti","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2230.2011.04074.x","article-title":"Successful treatment with infliximab despite positive tuberculosis ELISpot results in a patient with pityriasis rubra pilaris taking prophylactic isoniazid","volume":"36","author":"Zirbs","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000346640","article-title":"Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition","volume":"226","author":"Adnot-Desanlis","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.03.036_bib39","first-page":"217","article-title":"New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris","volume":"12","author":"Mattox","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1684\/ejd.2013.2175","article-title":"Pityriasis rubra pilaris types 1\u00a0and 2: different responses to treatment with TNF-alpha antagonists","volume":"23","author":"Vujic","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib41","first-page":"E6","article-title":"Pityriasis rubra pilaris triggered by photodynamic therapy with response to tumor necrosis factor \u03b1-blocking agents and acitretin","volume":"93","author":"L\u00f3pez-Ferrer","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2018.03.036_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamadermatol.2013.4773","article-title":"Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center","volume":"150","author":"Eastham","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/1346-8138.12927","article-title":"Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and\u00a0acitretin combination therapy","volume":"42","author":"Byekova","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamadermatol.2015.3405","article-title":"Treatment of refractory pityriasis rubra pilaris with novel phosphodiesterase 4 (PDE4) inhibitor apremilast","volume":"152","author":"Krase","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/0378-6323.157457","article-title":"Erythrodermic pityriasis rubra pilaris: dramatic response to infliximab therapy","volume":"82","author":"Karadag","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2018.03.036_bib46","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/jdv.14009","article-title":"Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT)","volume":"31","author":"Paganelli","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib47","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archderm.143.12.1597","article-title":"Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy","volume":"143","author":"Davis","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib48","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2133.2007.08379.x","article-title":"Successful use of etanercept in type I pityriasis rubra pilaris","volume":"158","author":"Seckin","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib49","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.jaad.2008.06.016","article-title":"Treatment of juvenile pityriasis rubra pilaris with etanercept","volume":"59","author":"Cox","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1529-8019.2011.01404.x","article-title":"Therapeutic hotline. Treatment of pityriasis rubra pilaris with etanercept","volume":"24","author":"Guedes","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.03.036_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2340\/00015555-1367","article-title":"Etanercept-induced clinical remission of type II pityriasis rubra pilaris with rheumatoid arthritis","volume":"92","author":"Kim","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.03.036_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2012.09.018","article-title":"Pityriasis rubra pilaris with polyarthritis treated with adalimumab","volume":"68","author":"Chiu","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib53","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/1346-8138.13038","article-title":"Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient","volume":"42","author":"Kim","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib54","article-title":"A case of juvenile pityriasis rubra pilaris type III successfully treated with etanercept","author":"Lora","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.03.036_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archdermatol.2008.527","article-title":"Pityriasis rubra pilaris responding rapidly to adalimumab","volume":"145","author":"Walling","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib56","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/j.1365-2230.2009.03747.x","article-title":"Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment","volume":"35","author":"O'Kane","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib57","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2230.2010.03806.x","article-title":"Pityriasis rubra pilaris successfully treated with adalimumab","volume":"35","author":"Schreml","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2310\/7750.2010.09023","article-title":"Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy","volume":"14","author":"Zhang","year":"2010","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2018.03.036_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000327704","article-title":"Oral alitretinoin for the treatment of recalcitrant pityriasis rubra pilaris","volume":"3","author":"Schmitt","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib60","first-page":"244","article-title":"Adalimumab for the treatment of pityriasis rubra pilaris: a case report","volume":"90","author":"Wassef","year":"2012","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2018.03.036_bib61","first-page":"22374","article-title":"Successful treatment of\u00a0pityriasis rubra pilaris with adalimumab- case report","volume":"20","author":"Bravo","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2018.03.036_bib62","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-4632.2012.05811.x","article-title":"Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon","volume":"53","author":"Marrouche","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib63","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1346-8138.13478","article-title":"Case of pityriasis rubra pilaris with annular pattern as an early manifestation","volume":"44","author":"Kitayama","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib64","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/09546634.2017.1303572","article-title":"High grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris","volume":"28","author":"Nic Dhonncha","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.03.036_bib65","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.2010.09855.x","article-title":"Treatment of pityriasis rubra pilaris with ustekinumab","volume":"163","author":"Wohlrab","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib66","first-page":"630","article-title":"Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy","volume":"20","author":"Ruiz Villaverde","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3315\/jdcr.2013.1127","article-title":"Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris","volume":"7","author":"Di Stefani","year":"2013","journal-title":"J Dermatol Case Rep"},{"key":"10.1016\/j.jaad.2018.03.036_bib68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000381011","article-title":"Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris","volume":"7","author":"Chowdhary","year":"2015","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/2229-5178.156410","article-title":"Ineffectiveness of tumor necrosis factor-\u03b1 blockers and ustekinumab in a case of type IV pityriasis rubra pilaris","volume":"6","author":"Di Lernia","year":"2015","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaad.2018.03.036_bib70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000102039","article-title":"Exacerbation of pityriasis rubra pilaris under efalizumab therapy","volume":"215","author":"Klein","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.03.036_bib71","first-page":"337","article-title":"Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient","volume":"6","author":"G\u00f3mez","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.gtc.2014.05.001","article-title":"Risk of infections with biological agents","volume":"43","author":"Kopylov","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jaad.2018.03.036_bib73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1600-0560.2012.01894.x","article-title":"Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists","volume":"39","author":"Hawryluk","year":"2012","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2018.03.036_bib74","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ced.13009","article-title":"Paraneoplastic pityriasis rubra pilaris: case report and literature review","volume":"42","author":"Bar-Ilan","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.036_bib75","doi-asserted-by":"crossref","first-page":"e12443","DOI":"10.1111\/dth.12443","article-title":"Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu's arteritis","volume":"30","author":"Salman","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.03.036_bib76","first-page":"335","article-title":"Bevacizumab-induced pityriasis rubra pilaris-like eruption","volume":"29","author":"Brown","year":"2016","journal-title":"Proc (Bayl Univ Med Cent)"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218304900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218304900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:47:06Z","timestamp":1759272426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218304900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0190962218304900"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.036","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for pityriasis rubra pilaris treatment: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}